Non-invasive score, Advanced fibrosis and MASLD

Non-invasive scores, advanced fibrosis, and metabolic dysfunction-associated steatotic liver disease (MASLD) are interrelated concepts in the context of liver disease diagnosis and management. Here's a detailed explanation of these terms and their relevance based on the provided context:

---

### **1. Non-Invasive Scores:**

Non-invasive fibrosis scoring tools are diagnostic methods designed to assess liver fibrosis severity without requiring a liver biopsy. These tools are based on clinical and laboratory parameters and are widely used due to their safety, cost-effectiveness, and accessibility. The study evaluated the following four non-invasive scoring tools:

• **Fibrosis-4 (Fib-4):** Incorporates age, AST (aspartate aminotransferase), ALT (alanine aminotransferase), and platelet count. It is particularly effective in younger patients for ruling out advanced fibrosis, with an excellent negative predictive value (NPV) of 97.5% in this group. However, its sensitivity (10%) is poor overall, making it less effective for confirming advanced fibrosis.

• **Nonalcoholic Fatty Liver Disease Fibrosis Score (NFS):** Includes variables such as age, BMI, AST/ALT ratio, platelet count, and albumin. It has strong NPV (96.5%) for excluding advanced fibrosis but suffers from low sensitivity (50%) and specificity (54%). Indeterminate results are common, especially in older adults.

• **AST-to-Platelet Ratio Index (APRI):** A simple score based on AST levels and platelet count. It has balanced sensitivity (72.7%) and excellent NPV (97.6%), making it useful for excluding advanced fibrosis. However, its specificity (50.2%) and overall discriminatory accuracy (AUROC 51.2%) are suboptimal.

• **BARD Score:** Combines BMI, AST/ALT ratio, and diabetes status. It has a sensitivity of 72.7% and an NPV of 95.5%, but its specificity (37.2%) and positive predictive value (PPV) (6.9%) are very low, limiting its ability to confirm advanced fibrosis.

These scores are primarily used as **screening tools** to rule out advanced fibrosis and reduce the need for liver biopsies in primary care settings.

---

### **2. Advanced Fibrosis:**

Advanced fibrosis refers to severe scarring of the liver, categorized as stages F3 and F4 in the Metavir scoring system. F3 indicates bridging fibrosis, while F4 represents cirrhosis, the most advanced stage of liver fibrosis. Advanced fibrosis is a critical stage because it significantly increases the risk of liver-related complications, such as liver failure, portal hypertension, and hepatocellular carcinoma (HCC).

In the study, the prevalence of advanced fibrosis was relatively low (~4–6%) in the cohort. This low prevalence contributed to the poor positive predictive values (PPVs) of the non-invasive scores, as false positives were frequent. Despite this limitation, the high NPVs of these tools (all above 90%) make them effective for **excluding advanced fibrosis**, particularly in younger patients.

---

### **3. MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease):**

MASLD is a recently introduced term that encompasses liver diseases previously classified under nonalcoholic fatty liver disease (NAFLD). MASLD is characterized by the accumulation of fat in the liver (steatosis) in the presence of metabolic dysfunction, such as obesity, diabetes, hypertension, and dyslipidemia. When inflammation and liver cell damage are also present, the condition is referred to as metabolic dysfunction-associated steatohepatitis (MASH), which is more severe and associated with a higher risk of fibrosis progression.

The study cohort consisted of patients with biopsy-proven MASLD or MASH. Key demographic characteristics included:

• Mean age: 53 years
• Female predominance: 62%
• High prevalence of obesity (75%), hypertension (63%), diabetes, and dyslipidemia, consistent with metabolic syndrome.

---

### **Key Findings and Clinical Implications:**

1. **Role of Non-Invasive Scores in MASLD/MASH:**

• Non-invasive scores like Fib-4, NFS, APRI, and BARD are valuable tools for initial screening of fibrosis in MASLD/MASH patients.
• These scores are particularly effective in ruling out advanced fibrosis due to their high NPVs (>90%), which can help reduce the need for invasive liver biopsies.

2. **Limitations in Confirming Advanced Fibrosis:**

• All four scores had poor sensitivity and specificity for identifying advanced fibrosis, limiting their utility as standalone confirmatory tests.
• The low prevalence of advanced fibrosis in the study population (~4–6%) further contributed to their poor PPVs.

3. **Age-Related Considerations:**

• Age ≥45 years was identified as a significant determinant of fibrosis severity. Older adults with metabolic risk factors (e.g., diabetes and obesity) had a higher prevalence of advanced fibrosis.
• However, the inclusion of age in scoring formulas may lead to overestimation of fibrosis in older adults, necessitating adjusted cutoffs or the use of complementary imaging techniques like transient elastography.

4. **Integration with Advanced Non-Invasive Tests:**

• To improve diagnostic accuracy, the study recommends combining these scores with advanced non-invasive tools such as:
• **Enhanced Liver Fibrosis (ELF) test**
• **Agile 3+/4 scores**
• **Transient elastography (FibroScan)**
• These advanced modalities provide more precise staging of fibrosis and are valuable for comprehensive evaluation and management of MASLD/MASH.

---

### **Conclusion:**

Non-invasive fibrosis scores (Fib-4, NFS, APRI, and BARD) play a critical role in the management of MASLD/MASH by effectively excluding advanced fibrosis, particularly in younger patients. However, their limited sensitivity, specificity, and confirmatory power necessitate integration with advanced diagnostic tools for accurate staging and risk stratification. Age and metabolic risk factors should also be considered when interpreting these scores, as they significantly influence fibrosis progression and diagnostic accuracy.